New President & CEO at Arbutus Bio | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34639 of 34682  at  6/17/2019 10:30:22 AM  by

The Rooster


 In response to msg 34638 by  Southerncross1
view thread

Re: New President & CEO at Arbutus Bio

The worrying thing to me is that they apparently decided this retirement last week (finalized on June 13).  And so, did they have an early look at the AB-506 capsid inhibitor data and was not good?  I hope not but time will tell very shortly:
 
"AB-506 showed attractive potency and PK in preclinical studies and has advanced into clinical development in a Phase 1a/1b study, initially in healthy volunteers followed by HBV patients. Top-line data from this ongoing study are anticipated in July 2019. Arbutus subsequently plans to evaluate a combination regimen, combining AB-506 with RNAi agent AB-729 and approved nucleoside analogs, with the goal of increasing cure rates in HBV patients." 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 177
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
34640 Re: New President & CEO at Arbutus Bio wbart21 4 6/17/2019 10:54:12 AM


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...